# Curis Cash Runway Drives Investor Test

> Curis' cash runway and clinical progress determine investor confidence after Q2 2026 earnings.
- Title: Curis Cash Runway Drives Investor Test | Shortify
- Summary: Curis' cash runway and clinical progress determine investor confidence after Q2 2026 earnings. Curis needs emavusertib clinical progress to secure funding…
- Keywords: curis, emavusertib, cash runway, nasdaq, clinical trials, pharmaceuticals, biotechnology, Cash, Runway, Drives, Investor, Test
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/curis-cris-earnings-results-cash-runway-is-the-main-investor-test
- Author: Newsdesk
- Published: 2026-10-08T19:47:14+00:00
- Read time: 1 min
- Topics: curis, emavusertib, cash runway, nasdaq, clinical trials, pharmaceuticals, biotechnology
## Q2 2026 Earnings Results
Curis reported no revenue in Q2 2026 after Erivedge royalty sale ended revenue stream.

> Q2 2026 revenue was zero after the Erivedge royalty sale
## Operating Expenses Tightened
Q2 2026 R&D expense fell to $6.7 million from $7.5 million, with total operating expenses at $9.9 million.
## Q2 2026 Net Loss
Curis posted a Q2 2026 GAAP net loss of $8.6 million, or $4.02 per share, after share count changes.
## Cash Runway Constraint
Curis ended Q2 2026 with $5.1 million cash, but August 2026 offering only extends runway to Q4 2026.
## Going-Concern Warning
Curis stated it lacks sufficient cash to fund operations for 12 months and faces substantial doubt about continuing as a going concern.
## Investor Focus on Clinical Progress
Curis needs emavusertib clinical trial success to secure funding before cash runway expires in Q4 2026.
## Key takeaway

Curis needs emavusertib clinical progress to secure funding before its cash runway expires in Q4 2026.